Loading
A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), now completed.
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma is a phase 3 interventional study registered as NCT04724369 by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), with 43 participants enrolled, started 2021-11-18 and reached its primary completion in 2026-07-30. Interventions recorded: 18F-MFBG.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares Neuroblastoma (paediatric) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.